Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis

Burmester, G. R. et al. (2018) Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis. Arthritis and Rheumatology, 70(5), pp. 679-689. (doi:10.1002/art.40420) (PMID:29361199)

[img]
Preview
Text
156349.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

601kB

Abstract

Objective: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor alpha. We report mavrilimumab long-term safety and efficacy in rheumatoid arthritis patients in two phase IIb studies (1071, 1107) and open-label extension (OLE; NCT01712399). Methods: In 1071, patients with disease-modifying antirheumatic drug (DMARD)-inadequate responses received mavrilimumab 30, 100, 150 mg, or placebo every other week (eow), plus methotrexate. In 1107, patients with anti-tumor necrosis factor agent- and/or DMARD-inadequate responses received mavrilimumab 100 mg eow or golimumab 50 mg every 4 weeks, plus methotrexate. Patients entering the OLE received mavrilimumab 100 mg eow plus methotrexate. Mavrilimumab long-term safety and efficacy were assessed. Results: In total, 442 patients received mavrilimumab (14/245 patients from 1071, 9/70 from 1107, 52/397 from OLE discontinued mavrilimumab treatment throughout the studies). The cumulative safety exposure was 899 patient-years (PY); the median duration of mavrilimumab treatment was 2.5 (range 0.1–3.3) years. Most common treatment-emergent adverse events were nasopharyngitis (n=69, 7.68/100 PY), bronchitis (n=51, 5.68/100 PY). At Weeks 74/104: 3.5%/6.2% patients showed reduction in forced expiratory volume in 1 second; 2.9%/3.4% patients showed reduction in forced vital capacity, respectively (>20% reduction from baseline to <80% predicted). Most pulmonary changes were transient and only infrequently associated with adverse events. Mavrilimumab 100 mg eow demonstrated sustained efficacy; 65.0% and 40.6% patients achieved Disease Activity Score 28–C-reactive protein <3.2 and <2.6, respectively at Week 122. Conclusion: Mavrilimumab long-term treatment maintained response and was well-tolerated with no TEAE incidence increase. Safety data were comparable with both phase IIb qualifying studies.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain
Authors: Burmester, G. R., McInnes, I. B., Kremer, J. M., Miranda, P., Vencovský, J., Godwood, A., Albulescu, M., Michaels, M. A., Guo, X., Close, D., and Weinblatt, M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Arthritis and Rheumatology
Publisher:Wiley
ISSN:2326-5191
ISSN (Online):2326-5205
Published Online:23 January 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Arthritis and Rheumatology 70(5):679-689
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record